TRCT
SNOA icon

Tower Research Capital (TRC)’s Sonoma Pharmaceuticals SNOA Stock Holding History

Tower Research Capital (TRC)’s Portfolio SNOA Stock Details SNOA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,231
Closed -$2.62K – 5612
2026
Q1 		$2.62K Buy
1,231
+846
+220% +$2.47K ﹤0.01% 4444
2025
Q4 		$1.4K Sell
385
-1,151
-75% -$4.25K ﹤0.01% 4699
2025
Q3 		$5.96K Buy
1,536
+536
+54% +$2.11K ﹤0.01% 4189
2025
Q2 		$2.85K Sell
1,000
-447
-31% -$1.35K ﹤0.01% 4584
2025
Q1 		$3.17K Sell
1,447
-960
-40% -$2.6K ﹤0.01% 4459
2024
Q4 		$6.47K Sell
2,407
-1,734
-42% -$4.88K ﹤0.01% 4167
2024
Q3 		$12.7K Buy
4,141
+3,728
+903% +$19K ﹤0.01% 3566
2024
Q2 		$1.75K Sell
413
-186
-31% -$662 ﹤0.01% 5096
2024
Q1 		$1.99K Buy
599
+123
+26% +$397 ﹤0.01% 5144
2023
Q4 		$1.71K Sell
476
-1
-0.2% -$6 ﹤0.01% 5336
2023
Q3 		$7.36K Buy
477
+48
+11% +$938 ﹤0.01% 4477
2023
Q2 		$9.18K Hold
429
– – ﹤0.01% 4326
2023
Q1 		$8K Buy
429
+26
+6% +$670 ﹤0.01% 4659
2022
Q4 		$9K Buy
403
+157
+64% +$5.59K ﹤0.01% 4264
2022
Q3 		$10K Buy
246
+220
+846% +$12.9K ﹤0.01% 4575
2022
Q2 		$2K Sell
26
-42
-62% -$2.69K ﹤0.01% 5601
2022
Q1 		$5K Buy
68
+42
+162% +$3.04K ﹤0.01% 5097
2021
Q4 		$2K Sell
26
-45
-63% -$4.81K ﹤0.01% 5664
2021
Q3 		$8K Buy
71
+66
+1,320% +$8.13K ﹤0.01% 4565
2021
Q2 		$1K Sell
5
-39
-89% -$6.12K ﹤0.01% 5256
2021
Q1 		$7K Buy
44
+8
+22% +$1.29K ﹤0.01% 4546
2020
Q4 		$5K Buy
+36
New +$5.47K ﹤0.01% 4639
2016
Q4 		– Sell
-2
Closed -$2K – 4364
2016
Q3 		$2K Buy
2
+1
+100% +$751 ﹤0.01% 3132
2016
Q2 		$1K Buy
+1
New +$861 ﹤0.01% 4210
2015
Q1 		– Sell
-3
Closed -$4K – 4879
2014
Q4 		$4K Buy
+3
New +$4.67K ﹤0.01% 2918
2014
Q3 		– Sell
-2
Closed -$4.65K – 4850
2014
Q2 		$6K Sell
2
-24
-92% -$71K ﹤0.01% 2742
2014
Q1 		$88K Buy
26
+25
+2,500% +$85K 0.01% 776
2013
Q4 		$2K Buy
+1
New +$2.66K ﹤0.01% 4045
2013
Q3 		– Sell
-8
Closed -$20K – 4817
2013
Q2 		$20K Buy
+8
New +$28.6K ﹤0.01% 1722

Other funds holding SNOA

Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MCWS
McKinley Carter Wealth Services Wheeling, West Virginia $1.94B AUM 20.7% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
GRP
Global Retirement Partners San Rafael, California $6.54B AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
HI
Harbour Investments Madison, Wisconsin $7.43B AUM 24.49% 1-Year Est. Return

Tower Research Capital (TRC)'s SNOA Position: Q2 2026 in Review

Tower Research Capital (TRC) sold out of Sonoma Pharmaceuticals (SNOA) in Q2 2026, closing a stake of 1,231 shares — an estimated $2.62K sold.

Tower Research Capital (TRC) first reported a position in SNOA in Q2 2013 and held it in 29 quarters. The position peaked at $88K in Q1 2014. 12 funds tracked by Wall St. Rank hold SNOA as of Q2 2026.

  • Tower Research Capital (TRC) reported no remaining Sonoma Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 1,231 Sonoma Pharmaceuticals shares in Q2 2026, an estimated $2.62K.
  • Tower Research Capital (TRC) first reported a position in Sonoma Pharmaceuticals in Q2 2013 and held it in 29 quarters.
  • Tower Research Capital (TRC)'s Sonoma Pharmaceuticals position peaked at $88K in Q1 2014.
  • 12 funds tracked by Wall St. Rank held Sonoma Pharmaceuticals as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.